Deals

Merck KGaA to Acquire Silence Therapeutics for USD 1.1 Billion Enterprise Value – Gaining Potential Best‑in‑Class siRNA Asset Divesiran
ETR: MRKMerck

Merck KGaA to Acquire Silence Therapeutics for USD 1.1 Billion Enterprise Value – Gaining Potential Best‑in‑Class siRNA Asset Divesiran

Merck KGaA (ETR: MRK) announced that it has entered into a definitive agreement to acquire Silence Therapeutics plc (NASDAQ: SLN), a UK‑headquartered global clinical‑stage biotechnology company pioneering siRNA therapies in…

Porton Advanced Solutions Partners with Hangzhou Aisijia Biotech on Diabetes Cell Therapy – CDMO to Provide Process Development, GMP Manufacturing and China IND Filing Support for Autologous Pancreatic Progenitor Cell Program

Porton Advanced Solutions Partners with Hangzhou Aisijia Biotech on Diabetes Cell Therapy – CDMO to Provide Process Development, GMP Manufacturing and China IND Filing Support for Autologous Pancreatic Progenitor Cell Program

Ascentage Pharma Signs Strategic Collaboration with Suzhou University and Its First Affiliated Hospital – Tripartite Partnership Targets Hematologic Oncology Innovation

Ascentage Pharma Signs Strategic Collaboration with Suzhou University and Its First Affiliated Hospital – Tripartite Partnership Targets Hematologic Oncology Innovation

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Kimia FarmaSHE: 300482

Guangzhou Wondfo Biotech Partners with Indonesia’s Kimia Farma in IVD Field

ADC / XDCGeneQuantum Healthcare

InxMed Partners with GeneQuantum Healthcare to Develop Innovative ADCs

Sansure BiotechSHA: 688289

Sansure Biotech Partners with Indonesian Firm for Localized Molecular Diagnostic Production

Cell-therapymRNA

NK Celltech and RongCan Biotech Partner to Advance mRNA NK Cell Therapy and LNP Delivery System

Show More